On October 28, Eastern Time, Recursion Pharmaceuticals options saw a total of 135193 contracts traded, with calls accounting for 92% and puts making up 7%.
Recursion Pharmaceuticals has 482638 contracts outstanding, with calls accounting for 79% and puts making up 20%.
The top volume gainer was the 6.5 dollars Call option expiring on October 31, 2025, with 3212 contracts traded.
On the news front, Based on recent key news:

1. Oct 28, Recursion Pharmaceuticals announced its upcoming Q3 financial results release on Nov 5, which may have influenced investor sentiment, leading to a stock price drop. The announcement was made via GlobeNewswire.

2. Oct 27, MarketBeat reported that Recursion Pharmaceuticals was not among the top stocks recommended by analysts, which may have contributed to the negative sentiment and stock decline.

3. Oct 26, Analysts maintained a Hold rating for Recursion Pharmaceuticals, suggesting limited upside potential compared to other stocks, impacting investor decisions.
Please note: The chart below does not include options expiring within five days.
<img src="https://assets.lbctrl.com/h5hub/optrank/images/2025-10-29/ST_US_RXRX_en.png" alt="image" original-src="https://assets.lbctrl.com/h5hub/optrank/images/2025-10-29/ST_US_RXRX_en.png"/>

RXRX

On October 28, Eastern Time, Recursion Pharmaceuticals options saw a total of 135193 contracts traded, with calls accounting for 92% and puts making up 7%.

Trending | RXRX Plummets 6% on Tuesday, Some Put options Surges 55%